目的 研究大珠红景天注射液联合辛伐他汀治疗慢性阻塞性肺疾病合并肺动脉高压的临床疗效。方法 选择2014年1月-2015年6月在保定市第二医院就诊的慢性阻塞性肺疾病合并肺动脉高压患者100例，随机分为对照组和治疗组，每组各50例。对照组口服辛伐他汀片，20 mg/次，1次/d；治疗组在对照组治疗基础上静脉滴注大株红景天注射液，10 mL/次加入5%葡萄糖注射液250 mL，1次/d。两组均连续治疗14 d。观察两组的临床疗效，同时比较两组治疗前后用力肺活量（FVC）、第1秒用力呼气容积（FEV₁）、肺活量百分比（FEV₁/FVC）、氧分压（pO₂）、二氧化碳分压（pCO₂）、血氧饱和度（SaO₂）、C-反应蛋白（CRP）、B型钠肽（NT-proBNP）、血浆内皮素-1（ET-1）、平均肺动脉压（mPAP）和呼吸困难指数评分的变化情况。结果 治疗后，对照组和治疗组总有效率分别为62.0%、82.0%，两组比较差异有统计学意义（P<0.05）。治疗后，两组FEVI、FEV¹/FVC、pO₂、SaO₂均显著升高，pCO₂、NT-proBNP、CRP、ET-1、mPAP、呼吸困难评分显著降低，同组治疗前后差异有统计学意义（P<0.05）。治疗后，治疗组这些观察指标的改善程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 大株红景天注射液联合辛伐他汀治疗慢性阻塞性肺疾病合并肺动脉高压具有较好的临床疗效，可显著改善患者的肺功能、肺动脉高压症状以及机体炎症反应，具有一定的临床推广应用价值。

Objective To study the effect of Sofren Injection combined with simvastatin in treatment of chronic obstructive pulmonary disease with pulmonary hypertension. Methods Patients (100 cases) with chronic obstructive pulmonary disease with pulmonary hypertension in the Second Hospital of Baoding from January 2014 to June 2015 were randomly divided into control and treatment groups, and each group had 50 cases. The patients in the control group were po administered with Simvastatin Tablets, 20 mg/time, once daily. The patients in the treatment group were iv administered with Sofren Injection on the basis of the control group, 10 mL/time added into 5% glucose injection 250 mL, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and the changes of FVC, FEV₁, FEV₁/FVC, pO₂, pCO₂, SaO₂, CRP, NT-proBNP, ET-1, mPAP, and dyspnea index scores in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 62.0% and 82.0%, respectively, and there were differences between two groups (P<0.05). After treatment, FEVI, FEV¹/FVC, pO₂, and SaO₂ in two groups were significantly increased, and pCO₂, NT-proBNP, CRP ET-1, mPAP, and dyspnea index scores were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Results Sofren Injection combined with simvastatin has clinical curative effect in treatment of chronic obstructive pulmonary disease with pulmonary hypertension, and can significantly improve lung function, pulmonary hypertension symptoms, and inflammatory response, which has a certain clinical application value.